Allarity Therapeutics (ALLR) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

ALLR · Stock Price

USD 1.50+0.42 (+38.89%)

Market Cap: $22.6M

Historical price data

Market Cap: $22.6MFounded: 2008Employees: 11-50HQ: Hørsholm, Denmark

Sector Ranking#130 in Diagnostics & Precision Medicine #144 in Oncology (General)

Overview

Allarity Therapeutics is a Danish clinical-stage biotech focused on personalizing cancer care by integrating its proprietary Drug Response Predictor (DRP®) diagnostic platform with targeted therapeutics. Its strategy centers on advancing stenoparib, a dual PARP/Tankyrase inhibitor, for advanced ovarian cancer, using a DRP® companion diagnostic to select patients most likely to respond. The company has achieved FDA Fast Track designation for stenoparib and is executing a focused Phase 2 trial, positioning it as a high-risk, high-reward player in precision oncology.

OncologyOvarian Cancer

Technology Platform

The Drug Response Predictor (DRP®) is a first-in-class, algorithm-based diagnostic platform that analyzes tumor RNA expression data to predict a patient's likelihood of responding to a specific cancer drug.

Funding History

2

Total raised:$20M

PIPE$5MUndisclosedMar 15, 2022

IPO$15MUndisclosedOct 15, 2021

Opportunities

If successful, stenoparib could address the significant unmet need of PARP inhibitor-resistant ovarian cancer, capturing a niche in a multi-billion dollar drug class.

The validated DRP® platform could also create long-term value through application to other internal or partnered drug candidates.

Risk Factors

The company faces extreme binary risk centered on the success of its single Phase 2 trial for stenoparib.

Its micro-cap status and pre-revenue nature create severe financial constraints and high risk of dilution, while competition in the ovarian cancer space is intense.

Competitive Landscape

Stenoparib competes directly with established PARP inhibitors in a crowded ovarian cancer market, requiring superior efficacy in a resistant population. The DRP® platform competes with other genomic profiling and companion diagnostic services, needing to prove its predictive superiority.